Hiten Shah, MD
Pulmonary Disease · Marion, OHNPI 1851343321
Payments from drug & device makers
Across 259 payments — averaging $15.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$1K
- Boehringer Ingelheim$246
- Grifols USA, LLC$232
- Sanofi$194
- Actelion Pharmaceuticals US, Inc.$176
- plus $1K from 22 others
What the payments were for
- Food & beverage$3,89597%
- Education$1223%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 54 | $1,089 |
| GSK | 95 | $1,061 |
| Boehringer Ingelheim | 15 | $246 |
| Grifols USA, LLC | 14 | $232 |
| Sanofi | 12 | $194 |
| Actelion Pharmaceuticals US, Inc. | 11 | $176 |
| Jazz Pharmaceuticals Inc. | 7 | $116 |
| Astellas Pharma US Inc | 2 | $113 |
| Philips North America LLC | 6 | $112 |
| Amgen | 6 | $92 |
| Mylan Specialty L.p. | 4 | $61 |
| Regeneron Healthcare Solutions, Inc. | 4 | $60 |
| Genentech USA, Inc. | 4 | $58 |
| Teva Pharmaceuticals USA, Inc. | 3 | $45 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $33 |
| Gilead | 2 | $31 |
| Bayer | 2 | $31 |
| Sunovion Pharmaceuticals Inc. | 2 | $31 |
| Advanced Respiratory, Inc | 3 | $31 |
| Inspire Medical Systems, Inc. | 1 | $30 |
| Circassia Inc. | 2 | $27 |
| Electromed, Inc. | 2 | $26 |
| Shionogi Inc | 1 | $26 |
| Olympus America Inc. | 1 | $24 |
| United Therapeutics Corporation | 1 | $22 |
| Sanofi Pasteur Inc. | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $15 |
| Mallinckrodt Hospital Products Inc. | 1 | $14 |
How this compares
$4,017 in reported general payments places this provider in the 55th percentile of 571 pulmonary disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 481 | $326,513 |
| Breo ElliptaFluticasone/Vilanterol | 257 | $120,723 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 169 | $118,119 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 109 | $52,421 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 63 | $38,228 |
| SymbicortBudesonide/Formoterol Fumarate | 116 | $31,156 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 30 | $25,807 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 825 | $20,423 |
| Spiriva RespimatTiotropium Bromide | 19 | $15,987 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 121 | $13,199 |
| Advair HfaFluticasone Propion/Salmeterol | 27 | $11,767 |
| Spiriva HandihalerTiotropium Bromide | 11 | $11,502 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 83 | $10,187 |
| Ventolin HfaAlbuterol Sulfate | 153 | $9,396 |
| Fluticasone-VilanterolFluticasone/Vilanterol | 22 | $8,046 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $1,061 | $499,657847 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,089 | $149,276285 claims |
| Boehringer IngelheimStiolto Respimat, Combivent Respimat, Spiriva Respimat | $246 | $80,021112 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $45 | $5,24222 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 571 pulmonary disease providers in Ohio.
Other pulmonary disease in Marion
- Harsh ShahMarion$183K
- Bruce CorserCincinnati$8.2M
- Edward CordascoColumbus$8M
- Kristin HighlandCleveland$3.2M
- Brian ZenoColumbus$2.9M
- Jean ElwingCincinnati$2.4M
- Roy St JohnColumbus$1.9M
- Nishant GuptaCincinnati$1.5M
- Robert BaughmanCincinnati$1.1M
- Francis McCormackCincinnati$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.